Please use this identifier to cite or link to this item: https://bura.brunel.ac.uk/handle/2438/33822
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKadeřábková, Nikol-
dc.contributor.authorFurniss, R Christopher D-
dc.contributor.authorMaslova, Evgenia-
dc.contributor.authorPotter, Kathryn E-
dc.contributor.authorEisaiankhongi, Lara-
dc.contributor.authorBernal, Patricia-
dc.contributor.authorFilloux, Alain-
dc.contributor.authorLandeta, Cristina-
dc.contributor.authorGonzalez, Diego-
dc.contributor.authorMcCarthy, Ronan R-
dc.contributor.authorMavridou, Despoina AI-
dc.date.accessioned2026-09-04T16:26:03Z-
dc.date.available2026-09-04T16:26:03Z-
dc.date.issued2023-08-02-
dc.identifier.citationKadeřábková, N. et al. (2026) 'Antibiotic potentiation and inhibition of cross-resistance in pathogens associated with cystic fibrosis', eLife, 12, pp. 1–32. doi: 10.7554/elife.91082.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/33822-
dc.descriptionData availability: All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided.en_US
dc.descriptionVersion history: Sent for peer review: July 26, 2023 Preprint posted: August 2, 2023 Reviewed Preprint version 1: October 11, 2023 Reviewed Preprint version 2: September 11, 2025 Version of Record published: April 21, 2026en_US
dc.description.abstractCritical Gram-negative pathogens, like <i>Pseudomonas</i>, <i>Stenotrophomonas</i>, and <i>Burkholderia</i>, are now resistant to most antibiotics. Complex resistance profiles, together with synergistic interactions between these organisms, increase the likelihood of treatment failure in distinct infection settings, for example in the lungs of cystic fibrosis (CF) patients. Here, we discover that cell envelope protein homeostasis pathways underpin both antibiotic resistance and cross-protection in CF-associated bacteria. We find that inhibition of oxidative protein folding inactivates multiple species-specific resistance proteins. Using this strategy, we sensitize multidrug-resistant </i>Pseudomonas aeruginosa</i> to β-lactam antibiotics and demonstrate promise of new treatment avenues for the recalcitrant emerging pathogen <i>Stenotrophomonas maltophilia</i>. The same approach also inhibits cross-protection between resistant <i>S. maltophilia</i> and susceptible <i>P. aeruginosa</i>, allowing eradication of both commonly co-occurring CF-associated organisms. Our results provide the basis for the development of next-generation strategies that target antibiotic resistance, while also impairing specific interbacterial interactions that enhance the severity of polymicrobial infections.en_US
dc.description.sponsorshipInsects as models to study wound healing infection and the wound microbiome | Funder: National Centre for the Replacement Refinement and Reduction of Animals in Research | Grant ID: NC/V001582/1. Ronan R McCarthy: National Centre for the Replacement Refinement and Reduction of Animals in Research (NC/V001582/1); Biotechnology and Biological Sciences Research Council (BB/V007823/1); Academy of Medical Sciences (SBF006\1040); Medical Research Council (MR/Y001354/1); Diabetes UK (SBF006\1040); British Heart Foundation (SBF006\1040); The Government Department of Business, Energy and Industrial Strategy (SBF006\1040); Wellcome Trust (SBF006\1040).en_US
dc.format.extentpp. 1–32-
dc.format.mediumElectronic-
dc.languageEnglishen_US
dc.language.isoen_USen_US
dc.publishereLife Sciences Publicationsen_US
dc.rightsRe-use licence for this version: CC BY-
dc.rightsLicence for published version: CC BY-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectE. colien_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectStenotrophomonas maltophiliaen_US
dc.subjectantibioticsen_US
dc.subjectantimicrobial resistanceen_US
dc.subjectcystic fibrosisen_US
dc.subjectinfectious diseaseen_US
dc.subjectmicrobiologyen_US
dc.subjectpolymicrobial infectionsen_US
dc.subject.meshHumans-
dc.subject.meshPseudomonas aeruginosa-
dc.subject.meshStenotrophomonas maltophilia-
dc.subject.meshCystic Fibrosis-
dc.subject.meshAnti-Bacterial Agents-
dc.subject.meshMicrobial Sensitivity Tests-
dc.subject.meshDrug Resistance, Bacterial-
dc.subject.meshDrug Resistance, Multiple, Bacterial-
dc.subject.meshbeta Lactam Antibiotics-
dc.subject.meshCystic Fibrosis-
dc.subject.meshAnti-Bacterial Agents-
dc.subject.meshStenotrophomonas maltophilia-
dc.subject.meshPseudomonas aeruginosa-
dc.subject.meshHumans-
dc.subject.meshDrug Resistance, Bacterial-
dc.subject.meshDrug Resistance, Multiple, Bacterial-
dc.subject.meshbeta Lactam Antibiotics-
dc.subject.meshMicrobial Sensitivity Tests-
dc.subject.other0601 Biochemistry and Cell Biology-
dc.titleAntibiotic potentiation and inhibition of cross-resistance in pathogens associated with cystic fibrosisen_US
dc.typeArticleen_US
dc.date.dateAccepted2026-04-21-
dc.identifier.doihttps://doi.org/10.7554/elife.91082-
dc.relation.isPartOfeLifeen_US
pubs.publication-statusPublished online-
pubs.volume12-
dc.identifier.eissn2050-084X-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dcterms.dateAccepted2026-04-21-
dcterms.issued2023-08-02-
dc.date.updated2026-09-04T14:33:50Z-
dc.rights.holderKadeřábková, Furniss et al.-
dc.contributor.orcidKadeřábková, Nikol [0000-0002-1205-1644]-
dc.contributor.orcidMaslova, Evgenia [0009-0008-1885-3104]-
dc.contributor.orcidBernal, Patricia [0000-0002-6228-0496]-
dc.contributor.orcidFilloux, Alain [0000-0003-1307-0289]-
dc.contributor.orcidLandeta, Cristina [0000-0003-4065-9646]-
dc.contributor.orcidMcCarthy, Ronan R [0000-0002-7480-6352]-
dc.contributor.orcidMavridou, Despoina AI [0000-0002-7449-1151]-
dc.identifier.numberRP91082-
Appears in Collections:Department of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023, Kadeřábková, Furniss et al. This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.5.6 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons